GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hisamitsu Pharmaceutical Co Inc (TSE:4530) » Definitions » Piotroski F-Score

Hisamitsu Pharmaceutical Co (TSE:4530) Piotroski F-Score : 7 (As of May. 03, 2024)


View and export this data going back to 1962. Start your Free Trial

What is Hisamitsu Pharmaceutical Co Piotroski F-Score?

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Hisamitsu Pharmaceutical Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Hisamitsu Pharmaceutical Co's Piotroski F-Score or its related term are showing as below:

TSE:4530' s Piotroski F-Score Range Over the Past 10 Years
Min: 5   Med: 7   Max: 7
Current: 7

During the past 13 years, the highest Piotroski F-Score of Hisamitsu Pharmaceutical Co was 7. The lowest was 5. And the median was 7.


Hisamitsu Pharmaceutical Co Piotroski F-Score Historical Data

The historical data trend for Hisamitsu Pharmaceutical Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hisamitsu Pharmaceutical Co Piotroski F-Score Chart

Hisamitsu Pharmaceutical Co Annual Data
Trend Feb15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 5.00 6.00 7.00 7.00

Hisamitsu Pharmaceutical Co Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 - - - 7.00

Competitive Comparison of Hisamitsu Pharmaceutical Co's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Hisamitsu Pharmaceutical Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hisamitsu Pharmaceutical Co's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hisamitsu Pharmaceutical Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Hisamitsu Pharmaceutical Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Feb24) TTM:Last Year (Feb23) TTM:
Net Income was 円13,969 Mil.
Cash Flow from Operations was 円18,188 Mil.
Revenue was 円141,706 Mil.
Gross Profit was 円78,970 Mil.
Average Total Assets from the begining of this year (Feb23)
to the end of this year (Feb24) was (313917 + 328779) / 2 = 円321348 Mil.
Total Assets at the begining of this year (Feb23) was 円313,917 Mil.
Long-Term Debt & Capital Lease Obligation was 円679 Mil.
Total Current Assets was 円194,022 Mil.
Total Current Liabilities was 円45,938 Mil.
Net Income was 円11,742 Mil.

Revenue was 円128,330 Mil.
Gross Profit was 円72,699 Mil.
Average Total Assets from the begining of last year (Feb22)
to the end of last year (Feb23) was (302858 + 313917) / 2 = 円308387.5 Mil.
Total Assets at the begining of last year (Feb22) was 円302,858 Mil.
Long-Term Debt & Capital Lease Obligation was 円897 Mil.
Total Current Assets was 円199,174 Mil.
Total Current Liabilities was 円42,578 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Hisamitsu Pharmaceutical Co's current Net Income (TTM) was 13,969. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Hisamitsu Pharmaceutical Co's current Cash Flow from Operations (TTM) was 18,188. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Feb23)
=13969/313917
=0.04449902

ROA (Last Year)=Net Income/Total Assets (Feb22)
=11742/302858
=0.03877064

Hisamitsu Pharmaceutical Co's return on assets of this year was 0.04449902. Hisamitsu Pharmaceutical Co's return on assets of last year was 0.03877064. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Hisamitsu Pharmaceutical Co's current Net Income (TTM) was 13,969. Hisamitsu Pharmaceutical Co's current Cash Flow from Operations (TTM) was 18,188. ==> 18,188 > 13,969 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Feb24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Feb23 to Feb24
=679/321348
=0.00211297

Gearing (Last Year: Feb23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Feb22 to Feb23
=897/308387.5
=0.00290868

Hisamitsu Pharmaceutical Co's gearing of this year was 0.00211297. Hisamitsu Pharmaceutical Co's gearing of last year was 0.00290868. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Feb24)=Total Current Assets/Total Current Liabilities
=194022/45938
=4.22356219

Current Ratio (Last Year: Feb23)=Total Current Assets/Total Current Liabilities
=199174/42578
=4.67786181

Hisamitsu Pharmaceutical Co's current ratio of this year was 4.22356219. Hisamitsu Pharmaceutical Co's current ratio of last year was 4.67786181. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Hisamitsu Pharmaceutical Co's number of shares in issue this year was 75.743. Hisamitsu Pharmaceutical Co's number of shares in issue last year was 79.402. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=78970/141706
=0.55728057

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=72699/128330
=0.56650043

Hisamitsu Pharmaceutical Co's gross margin of this year was 0.55728057. Hisamitsu Pharmaceutical Co's gross margin of last year was 0.56650043. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Feb23)
=141706/313917
=0.45141232

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Feb22)
=128330/302858
=0.42372993

Hisamitsu Pharmaceutical Co's asset turnover of this year was 0.45141232. Hisamitsu Pharmaceutical Co's asset turnover of last year was 0.42372993. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+0+1+0+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Hisamitsu Pharmaceutical Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Hisamitsu Pharmaceutical Co  (TSE:4530) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Hisamitsu Pharmaceutical Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Hisamitsu Pharmaceutical Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Hisamitsu Pharmaceutical Co (TSE:4530) Business Description

Traded in Other Exchanges
Address
408 Tashiro Daikan-machi, Tosu, Saga, JPN, 841-0017
Hisamitsu Pharmaceutical Co Inc is a major pharmaceutical products manufacturer in Japan. The company collaborates with its subsidiaries and associates in operating its business across two segments, The Medical and Related Product segment and the Others segment. The Medical segment represents the company's foremost revenue generating operations. It markets drugs under the Salanpas, Salonsip, Lifecella, Mohrus and Keplat brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions and ointments. The Others segment refers to its miscellaneous businesses such as cable television broadcasting, internet connection, packing materials and insurance. Apart from its primary market in Japan, Hisamitsu has a reach across other regions like North America.

Hisamitsu Pharmaceutical Co (TSE:4530) Headlines

No Headlines